<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23083" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hydroxocobalamin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ramezanpour Ahangar</surname>
            <given-names>Edris</given-names>
          </name>
          <aff>Hull York Medical School</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Annamaraju</surname>
            <given-names>Pavan</given-names>
          </name>
          <aff>Loma Linda University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Edris Ramezanpour Ahangar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pavan Annamaraju declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23083.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Hydroxocobalamin is a medication used in the management and treatment of vitamin B12 deficiency and acute cyanide toxicity. It is in the anti-anemic class of drugs. This activity outlines the indications, action, and contraindications for hydroxocobalamin as a valuable agent in managing macrocytic anemia and acute cyanide toxicity. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team) in the treatment of patients with vitamin B12 deficiency and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of hydroxocobalamin.</p></list-item><list-item><p>Describe the potential adverse effects of hydroxocobalamin.</p></list-item><list-item><p>Review the appropriate monitoring for patients using hydroxocobalamin.</p></list-item><list-item><p>Explain the importance of collaboration and communication amongst the interprofessional team to improve outcomes for patients receiving hydroxocobalamin.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23083&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23083">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23083.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Hydroxocobalamin is a form of manufactured, injectable vitamin B12. Clinicians use it in the prevention and treatment of macrocytic anemia associated with vitamin B12 deficiency. It may also be part of therapy to treat Leber optic atrophy (an inherited optic neuropathy associated with a deficiency in vitamin B12).<xref ref-type="bibr" rid="article-23083.r1">[1]</xref> It is also an antidote in cases of cyanide poisoning,<xref ref-type="bibr" rid="article-23083.r2">[2]</xref>&#x000a0;including&#x000a0;nutritional optic neuropathy (a visual disorder caused by tobacco that contained cyanide).<xref ref-type="bibr" rid="article-23083.r3">[3]</xref>&#x000a0;Hydroxocobalamin is particularly useful in the treatment of vitamin B12 deficiency secondary to conditions that impair the absorption of vitamin B12 from the GI tract, including malabsorption and pernicious anemia.</p>
        <p>The FDA-approved form of intravenous (IV) hydroxocobalamin is used for the treatment of cyanide poisoning.<xref ref-type="bibr" rid="article-23083.r4">[4]</xref></p>
      </sec>
      <sec id="article-23083.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Hydroxocobalamin is a precursor of methylcobalamin and adenosylcobalamin, which are the active forms of vitamin B12.<xref ref-type="bibr" rid="article-23083.r5">[5]</xref>&#x000a0;Methylcobalamin and adenosylcobalamin are both cofactors involved in DNA and amino acid synthesis, fatty acid metabolism, and maintenance of nerve function.<xref ref-type="bibr" rid="article-23083.r6">[6]</xref>&#x000a0;The methylcobalamin component in hydroxocobalamin plays a role in the development of the nervous system during childhood and hematopoiesis. Adenosylcobalamin is involved with the metabolism of carbohydrates, amino acids, and fatty acids and is thus, involved in myelin formation. Therefore, the role of vitamin B12 highlights the clinical features that may present in vitamin B12 deficiency and the indications for the use of hydroxocobalamin. Methylcobalamin is a cofactor for the enzyme methionine synthase, an essential enzyme in the formation of methionine from homocysteine. This reaction is critical in the synthesis of purines and pyrimidines needed for DNA synthesis and red blood cell formation.<xref ref-type="bibr" rid="article-23083.r7">[7]</xref></p>
        <p>Hydroxocobalamin can serve as an antidote&#x000a0;for cyanide poisoning.<xref ref-type="bibr" rid="article-23083.r2">[2]</xref>&#x000a0;Cyanide binds to the cytochrome c oxidase, a terminal complex in the electron transport chain. This process leads to inhibition of&#x000a0;ATP production and cellular oxygen utilization. As a result, cellular respiration becomes blocked, resulting in rapid death. Hydroxocobalamin contains cobalt compounds that can bind to and detoxify cyanide by intercepting the cyanide before it inhibits cellular respiration.<xref ref-type="bibr" rid="article-23083.r8">[8]</xref>&#x000a0;The hydroxocobalamin rapidly forms cyanocobalamin by removing the cyanide from tissues. The kidneys then excrete the cyanocobalamin in the urine.<xref ref-type="bibr" rid="article-23083.r4">[4]</xref></p>
        <p>Hydroxocobalamin binds to transcobalamins. Transcobalamin-II is the main serum transport protein that delivers hydroxocobalamin to the tissues.<xref ref-type="bibr" rid="article-23083.r9">[9]</xref>&#x000a0;Vitamin B12 is stored in the liver and secreted into bile, where it undergoes recycling via the enterohepatic circulation. Its excretion is predominantly via the fecal route. Elevated levels of B12 can occur with parenteral administration. In such cases, the kidneys excrete any excess circulating B12 into the urine.<xref ref-type="bibr" rid="article-23083.r10">[10]</xref></p>
      </sec>
      <sec id="article-23083.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Hydroxocobalamin is given parenterally, either as an intramuscular or intravenous injection. Cyanocobalmin administration can be via the oral, sublingual, intramuscular, or subcutaneous routes. Cyanocobalamin use is common in the United States, whereas hydroxocobalamin is the more preferred formulation in Europe for the treatment of vitamin B12 deficiency. Hydroxocobalamin requires less frequent administration (every three months) compared to oral cyanocobalamin supplementation. The parenteral method of administration is particularly useful to treat vitamin B12 deficiency caused by malabsorption states in which oral administration is ineffective.<xref ref-type="bibr" rid="article-23083.r11">[11]</xref></p>
        <p>When treating vitamin B12 deficiency anemia with hydroxocobalamin, the dosage of each intramuscular injection of hydroxocobalamin is usually 1 mg given as a total of 5 to 10&#x000a0;doses administered every other day (3 times a week over two weeks)&#x000a0;followed by every three months after that for maintenance. The duration of treatment is assessed based on the patient&#x02019;s therapeutic response.<xref ref-type="bibr" rid="article-23083.r12">[12]</xref></p>
        <p>The recommendation is to take the following precautions when treating B12 or folate deficiency.&#x000a0;</p>
        <p>In a patient with folate deficiency, evaluation for coexistent B12 deficiency is necessary. If folate alone is supplemented in a B12 deficient patient, the B12 associated hematologic abnormalities may improve; however, neurological symptoms can&#x000a0;worsen.&#x000a0;&#x000a0;</p>
        <p>One of the neurological disorders associated with B12 deficiency is subacute combined degeneration of the cord (SCD), a condition characterized by demyelination of the dorsal and lateral columns of the spinal cord. B12 plays a vital role in myelin production. The active form of B12 (adenosylcobalamin) serves as a cofactor in converting methylmalonyl-CoA to succinyl-CoA, an essential step in lipid synthesis. Without adenosylcobalamin, abnormal fatty acids incorporate into neuronal lipids interfering with normal myelin formation. Additionally, B12 deficiency can cause abnormal DNA synthesis, potentially hindering oligodendrocyte growth, adversely affecting myelin production.</p>
        <p>Alternatively, it is also essential to recognize that folate deficiency indirectly leads to a B12 deficient state. In the cells, folate converts to its active form methyltetrahydrofolate (MTHF). MTHF acts as a donor of methyl groups to B12 (cobalamin), forming methylcobalamin. In the absence of this methylation, methylcobalamin (active form) is not produced and is unavailable for use leading to signs and symptoms of B12 deficiency.<xref ref-type="bibr" rid="article-23083.r13">[13]</xref></p>
        <p>In cyanide poisoning, intravenous (IV) hydroxocobalamin should be used. The FDA approves the immediate use of an injection kit for this purpose.<xref ref-type="bibr" rid="article-23083.r4">[4]</xref></p>
      </sec>
      <sec id="article-23083.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Hydroxocobalamin is generally a well-tolerated drug. The adverse effects stem from hypersensitivity reactions to cobalt or other components of the hydroxocobalamin injection. These adverse effects include; exanthema (rash), Itching, fever, nausea, dizziness, rigors, and hot flushes. Anaphylaxis is rare.<xref ref-type="bibr" rid="article-23083.r14">[14]</xref></p>
        <p>Intramuscular injections can be painful for the patient. There is a risk of needle stick injury to the healthcare professionals delivering the injection. Further, it is associated with higher costs as it typically requires administration by a trained professional at home or a healthcare facility.<xref ref-type="bibr" rid="article-23083.r15">[15]</xref><xref ref-type="bibr" rid="article-23083.r11">[11]</xref></p>
      </sec>
      <sec id="article-23083.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are no absolute contraindications to the use of hydroxocobalamin.</p>
        <p>If hypersensitivity to hydroxocobalamin or any of its components is suspected, the drug should be avoided.</p>
      </sec>
      <sec id="article-23083.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>It is essential to confirm vitamin B12 deficiency before starting therapy and a follow-up plan for the monitoring of the patient&#x02019;s response. If there is severe anemia associated with vitamin B12 deficiency, the patient&#x02019;s response should lead to a marked increase in reticulocytes (precursors of red blood cells) by one-to-two weeks. In mild deficiencies of B12, this is less important, and follow-up should be done at two-to-three months after initiation of hydroxocobalamin. These measurements should include vitamin B12 levels as well as homocysteine and methylmalonic acid levels.<xref ref-type="bibr" rid="article-23083.r15">[15]</xref>&#x000a0;Both homocysteine and methylmalonic acid are indicators for vitamin B12 levels and demonstrate the patient&#x02019;s response to hydroxocobalamin.<xref ref-type="bibr" rid="article-23083.r7">[7]</xref></p>
      </sec>
      <sec id="article-23083.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There have been no reports of any known toxicity to hydroxocobalamin. As a result, there is no amount of hydroxocobalamin considered as a vitamin B12 overdose. There is no antidote.</p>
      </sec>
      <sec id="article-23083.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional team approach to managing patients requiring injections with hydroxocobalamin is essential in establishing an effective treatment regimen and assessment of patient response. This interprofessional team includes clinicians, mid-level practitioners, pharmacists, and nursing staff, all working collaboratively and sharing information to achieve optimal patient outcomes. It is important to emphasize that although rare, there may be hypersensitivity or allergic reactions to components of the hydroxocobalamin injection in some individuals. Open communication among members of the healthcare team is essential under these circumstances. There should be coordination between the nurse or practitioner administering the injection and the prescriber to ensure appropriate administration and monitoring of therapeutic response. The pharmacists can verify dosing and watch for potential interactions. All members can counsel the patient on administration and signs of therapeutic effectiveness as well as possible adverse reactions. There should be clear communication with patients on the quantity and frequency of injections needed. This information should be given initially by the prescriber and then again by the nurse or other healthcare provider administering the injection.</p>
      </sec>
      <sec id="article-23083.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23083&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23083">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23083/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23083">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23083.s11">
        <title>References</title>
        <ref id="article-23083.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pott</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Leber's hereditary optic neuropathy and vitamin B12 deficiency.</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>244</volume>
            <issue>10</issue>
            <fpage>1357</fpage>
            <page-range>1357-9</page-range>
            <pub-id pub-id-type="pmid">16523300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23083.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thompson</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Marrs</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Hydroxocobalamin in cyanide poisoning.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>50</volume>
            <issue>10</issue>
            <fpage>875</fpage>
            <page-range>875-85</page-range>
            <pub-id pub-id-type="pmid">23163594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23083.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rizzo</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lessell</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tobacco amblyopia.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1993</year>
            <month>Jul</month>
            <day>15</day>
            <volume>116</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-7</page-range>
            <pub-id pub-id-type="pmid">8328548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23083.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Purvis</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Rooks</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Young Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Longerich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Prehospital hydroxocobalamin for inhalation injury and cyanide toxicity in the United States - analysis of a database and survey of ems providers.</article-title>
            <source>Ann Burns Fire Disasters</source>
            <year>2017</year>
            <month>Jun</month>
            <day>30</day>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>126</fpage>
            <page-range>126-128</page-range>
            <pub-id pub-id-type="pmid">29021725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23083.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thakkar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Billa</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Treatment of vitamin B12 deficiency-methylcobalamine? Cyancobalamine? Hydroxocobalamin?-clearing the confusion.</article-title>
            <source>Eur J Clin Nutr</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-2</page-range>
            <pub-id pub-id-type="pmid">25117994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23083.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cassileth</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Vitamin B12.</article-title>
            <source>Oncology (Williston Park)</source>
            <year>2010</year>
            <month>Nov</month>
            <day>15</day>
            <volume>24</volume>
            <issue>12</issue>
            <fpage>1176</fpage>
            <pub-id pub-id-type="pmid">21141702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23083.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Leary</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Samman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Vitamin B12 in health and disease.</article-title>
            <source>Nutrients</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>299</fpage>
            <page-range>299-316</page-range>
            <pub-id pub-id-type="pmid">22254022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23083.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Gretarsdottir</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Chemical and Clinical Aspects of Metal-Containing Antidotes for Poisoning by Cyanide.</article-title>
            <source>Met Ions Life Sci</source>
            <year>2019</year>
            <month>Jan</month>
            <day>14</day>
            <volume>19</volume>
            <pub-id pub-id-type="pmid">30855115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23083.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teplitsky</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Huminer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zoldan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pitlik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shohat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mittelman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hereditary partial transcobalamin II deficiency with neurologic, mental and hematologic abnormalities in children and adults.</article-title>
            <source>Isr Med Assoc J</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>868</fpage>
            <page-range>868-72</page-range>
            <pub-id pub-id-type="pmid">14689755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23083.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <collab>Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline</collab>
            <source>Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B<sub>6</sub>, Folate, Vitamin B<sub>12</sub>, Pantothenic Acid, Biotin, and Choline</source>
            <publisher-name>National Academies Press (US)</publisher-name>
            <publisher-loc>Washington (DC)</publisher-loc>
            <year>1998</year>
            <pub-id pub-id-type="pmid">23193625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23083.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vidal-Alaball</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Cannings-John</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goringe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hood</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>McCaddon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McDowell</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Papaioannou</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2005</year>
            <month>Jul</month>
            <day>20</day>
            <issue>3</issue>
            <fpage>CD004655</fpage>
            <pub-id pub-id-type="pmid">16034940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23083.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skouby</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Dosage of hydroxocobalamin for vitamin B12 deficiency.</article-title>
            <source>Acta Med Scand</source>
            <year>1970</year>
            <season>Jul-Aug</season>
            <volume>188</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-6</page-range>
            <pub-id pub-id-type="pmid">5472640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23083.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marshall</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Milburn</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Clinical images - a quarterly column: subacute combined degeneration of the spinal cord.</article-title>
            <source>Ochsner J</source>
            <year>2013</year>
            <season>Summer</season>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-5</page-range>
            <pub-id pub-id-type="pmid">23789001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23083.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>James</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Warin</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Sensitivity to cyanocobalamin and hydroxocobalamin.</article-title>
            <source>Br Med J</source>
            <year>1971</year>
            <month>May</month>
            <day>01</day>
            <volume>2</volume>
            <issue>5756</issue>
            <fpage>262</fpage>
            <pub-id pub-id-type="pmid">5572387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23083.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Vitamin B12 deficiency.</article-title>
            <source>Am Fam Physician</source>
            <year>2003</year>
            <month>Mar</month>
            <day>01</day>
            <volume>67</volume>
            <issue>5</issue>
            <fpage>979</fpage>
            <page-range>979-86</page-range>
            <pub-id pub-id-type="pmid">12643357</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
